Novel PET Imaging Agent Targets Copper Atoms
|
By MedImaging International staff writers Posted on 21 Mar 2018 |
|
Image: 64CuCl2 PET/CT images reveal two positive small lymph nodes (A, C), whereas 18F-Choline PET/CT (B, D) is negative (Photo courtesy of Arnoldo Piccardo/ Galliera Hospital).
A novel positron emission tomography/computed tomography (PET/CT) imaging agent that traces copper accumulation in tumors can help detect prostate cancer (PC) recurrence, according to a new study.
Researchers at Galliera Hospital (Genoa, Italy), Humanitas Research Hospital (Milano, Italy), and other institutions conducted a study that prospectively evaluated 50 PC patients with relapse after surgery or external-beam radiation therapy (EBRT), as identified by rising prostate-specific antigen (PSA) levels. All patients underwent 64CuCl2 PET/CT, 18F-choline PET/CT, and multi-parametric magnetic resonance imaging (mpMRI) within a 15-day period in order to evaluate and compare the biodistribution, kinetics, and radiation dosimetry of 64CuCl2 in humans.
Experienced readers interpreted the images, and the detection rate of each imaging modality was then calculated. Histopathology, clinical or laboratory response, and multidisciplinary follow-up were used to confirm the site of disease. The results revealed that maximum 64CuCl2 uptake at PC sites relapse was observed one hour after tracer injection. 64CuCl2 PET/CT proved positive in 41 of 50 patients, with an overall detection rate of 82%; detection rates of 18F-choline PET/CT and mpMRI were 56% and 74%, respectively. The study was published in the March 2018 issue of The Journal of Nuclear Medicine.
“This study determined that the biodistribution of 64CuCl2 is more suitable than that of 18F-Choline for exploring the pelvis and prostatic bed,” said lead author Arnoldo Piccardo, MD, of Galliera Hospital. “Early detection of prostate cancer relapse may improve the clinical management of patients, for example implementing early salvage radiotherapy. Larger trials with this PET tracer are expected to further define its capabilities and role in the management of prostate cancer.”
Copper-64 is a positron-emitting isotope of copper, with applications for molecular radiotherapy and PET. The coordination chemistry of copper allows for its reaction with a wide variety of chelator systems that can be linked to antibodies, proteins, peptides, and other biologically relevant small molecules. The longer half-life of 64Cu delivers optimal bio-distribution of slower clearing agents, such as monoclonal antibodies, nanoparticles, and higher molecular weight polypeptides requiring longer imaging times.
Related Links:
Galliera Hospital
Humanitas Research Hospital
Researchers at Galliera Hospital (Genoa, Italy), Humanitas Research Hospital (Milano, Italy), and other institutions conducted a study that prospectively evaluated 50 PC patients with relapse after surgery or external-beam radiation therapy (EBRT), as identified by rising prostate-specific antigen (PSA) levels. All patients underwent 64CuCl2 PET/CT, 18F-choline PET/CT, and multi-parametric magnetic resonance imaging (mpMRI) within a 15-day period in order to evaluate and compare the biodistribution, kinetics, and radiation dosimetry of 64CuCl2 in humans.
Experienced readers interpreted the images, and the detection rate of each imaging modality was then calculated. Histopathology, clinical or laboratory response, and multidisciplinary follow-up were used to confirm the site of disease. The results revealed that maximum 64CuCl2 uptake at PC sites relapse was observed one hour after tracer injection. 64CuCl2 PET/CT proved positive in 41 of 50 patients, with an overall detection rate of 82%; detection rates of 18F-choline PET/CT and mpMRI were 56% and 74%, respectively. The study was published in the March 2018 issue of The Journal of Nuclear Medicine.
“This study determined that the biodistribution of 64CuCl2 is more suitable than that of 18F-Choline for exploring the pelvis and prostatic bed,” said lead author Arnoldo Piccardo, MD, of Galliera Hospital. “Early detection of prostate cancer relapse may improve the clinical management of patients, for example implementing early salvage radiotherapy. Larger trials with this PET tracer are expected to further define its capabilities and role in the management of prostate cancer.”
Copper-64 is a positron-emitting isotope of copper, with applications for molecular radiotherapy and PET. The coordination chemistry of copper allows for its reaction with a wide variety of chelator systems that can be linked to antibodies, proteins, peptides, and other biologically relevant small molecules. The longer half-life of 64Cu delivers optimal bio-distribution of slower clearing agents, such as monoclonal antibodies, nanoparticles, and higher molecular weight polypeptides requiring longer imaging times.
Related Links:
Galliera Hospital
Humanitas Research Hospital
Gold Member
Electrode Solution and Skin Prep
Signaspray
Gold Member
Ultrasound System
FUTUS LE
Mobile Imaging Table
medifa 8000 hybrid
Gold Member
CR Reader
FCR PRIMA II
Latest Nuclear Medicine News
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure
- New PET Radiotracer Aids Early, Noninvasive Detection of Inflammatory Bowel Disease
- Combining Amino Acid PET and MRI Imaging to Help Treat Aggressive Brain Tumors
Channels
Radiography
view channel
Novel Breast Imaging System Proves As Effective As Mammography
Breast cancer remains the most frequently diagnosed cancer among women. It is projected that one in eight women will be diagnosed with breast cancer during her lifetime, and one in 42 women who turn 50... Read more
AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
Radiologists typically detect one case of cancer for every 200 mammograms reviewed. However, these evaluations often result in false positives, leading to unnecessary patient recalls for additional testing,... Read more
MRI
view channel
PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
The Prostate Imaging Reporting and Data System (PI-RADS) is a five-point scale to assess potential prostate cancer in MR images. PI-RADS category 3 which offers an unclear suggestion of clinically significant... Read more
Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
Essential tremor, often called familial, idiopathic, or benign tremor, leads to uncontrollable shaking that significantly affects a person’s life. When traditional medications do not alleviate symptoms,... Read more
Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
Prostate cancer ranks as the most prevalent cancer among men. Over the last decade, the introduction of MRI scans has significantly transformed the diagnosis process, marking the most substantial advancement... Read more
Ultrasound
view channel
Deep Learning Advances Super-Resolution Ultrasound Imaging
Ultrasound localization microscopy (ULM) is an advanced imaging technique that offers high-resolution visualization of microvascular structures. It employs microbubbles, FDA-approved contrast agents, injected... Read more
Novel Ultrasound-Launched Targeted Nanoparticle Eliminates Biofilm and Bacterial Infection
Biofilms, formed by bacteria aggregating into dense communities for protection against harsh environmental conditions, are a significant contributor to various infectious diseases. Biofilms frequently... Read more
Nuclear Medicine
view channel
New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more
New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
Ovarian cancer is the most lethal gynecological cancer, with less than a 30% five-year survival rate for those diagnosed in late stages. Despite surgery and platinum-based chemotherapy being the standard... Read more
AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more
Imaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more
Industry News
view channel
Bayer and Google Partner on New AI Product for Radiologists
Medical imaging data comprises around 90% of all healthcare data, and it is a highly complex and rich clinical data modality and serves as a vital tool for diagnosing patients. Each year, billions of medical... Read more
